terbutaline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 2598 23031-25-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terbutaline
  • bricaril
  • terbutalin
  • brican
  • terbutaline sulfate
  • terbutaline hemisulfate
A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
  • Molecular weight: 225.29
  • Formula: C12H19NO3
  • CLOGP: 0.48
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -1.59
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg Inhal.aerosol
2 mg Inhal.powder
20 mg Inhal.solution
15 mg O
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 213 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 56 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.11 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.897 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.489 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.454 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 5.309 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 83.010 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 40.280 % High 1
herg hERG pIC50 4.053 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.673 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.767 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 74.300 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 64
kinase-selectivity-class ACVR2B,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.785 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.728 High 1
mh-clint Mouse hepatocyte intrinsic clearance 27.479 High 1
mppb Mouse plasma protein binding (% unbound) 79.590 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.661 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 80.940 % High 1
rat-kpuu-brain Rat brain Kpuu 0.026 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.767 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 86.480 % High 1
rppb Rat plasma protein binding (% unbound) 64.320 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 831.764 uM High 1

Approvals:

DateAgencyCompanyOrphan
March 25, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 243.57 16.35 214 10682 241946 90375605
Dyspnoea 139.63 16.35 318 10578 880637 89736914
Nasal discharge discolouration 86.90 16.35 26 10870 2827 90614724
Middle insomnia 78.65 16.35 39 10857 16712 90600839
Acute kidney injury 69.50 16.35 132 10764 320255 90297296
Cough 65.69 16.35 140 10756 368822 90248729
Wheezing 65.67 16.35 109 10787 237971 90379580
Lactic acidosis 63.74 16.35 51 10845 50412 90567139
Full blood count abnormal 61.79 16.35 44 10852 36553 90580998
Forced expiratory volume decreased 58.10 16.35 23 10873 5785 90611766
Decreased activity 56.86 16.35 25 10871 8167 90609384
Eosinophil count abnormal 54.73 16.35 14 10882 852 90616699
Tremor 51.73 16.35 77 10819 153096 90464455
Productive cough 50.55 16.35 54 10842 77009 90540542
Sputum discoloured 50.14 16.35 31 10865 20360 90597191
Obstructive airways disorder 48.09 16.35 33 10863 25836 90591715
Sleep disorder due to a general medical condition 45.69 16.35 40 10856 44698 90572853
Heart rate increased 42.85 16.35 60 10836 112842 90504709
Squamous cell carcinoma of the oral cavity 42.80 16.35 10 10886 416 90617135
Bronchospasm 37.51 16.35 26 10870 20683 90596868
Folate deficiency 36.86 16.35 14 10882 3151 90614400
Hyperlactacidaemia 36.61 16.35 15 10881 4121 90613430
Iodine allergy 35.53 16.35 10 10886 876 90616675
Palpitations 35.52 16.35 61 10835 136667 90480884
Allergy to metals 33.95 16.35 10 10886 1030 90616521
Shock haemorrhagic 33.67 16.35 20 10876 12225 90605326
Alopecia 33.64 16.35 9 10887 495062 90122489
Foetal exposure during pregnancy 33.39 16.35 33 10863 42942 90574609
Nasal congestion 32.64 16.35 45 10851 83369 90534182
Systemic lupus erythematosus 32.56 16.35 3 10893 361893 90255658
Emphysema 31.21 16.35 19 10877 12136 90605415
Fallopian tube disorder 30.67 16.35 8 10888 526 90617025
Pneumonia 30.31 16.35 154 10742 637905 89979646
Lung diffusion disorder 30.00 16.35 6 10890 118 90617433
Hepatocellular injury 29.78 16.35 26 10870 28932 90588619
Influenza 28.43 16.35 56 10840 139208 90478343
Glossodynia 28.08 16.35 3 10893 321776 90295775
Contraindicated product administered 27.89 16.35 3 10893 320136 90297415
Product administration error 27.73 16.35 24 10872 26399 90591152
Joint swelling 27.62 16.35 13 10883 503287 90114264
Toxic epidermal necrolysis 27.19 16.35 26 10870 32502 90585049
Pleural rub 27.09 16.35 5 10891 63 90617488
Tachycardia 27.02 16.35 59 10837 157614 90459937
Chest discomfort 26.28 16.35 54 10842 138311 90479240
Post viral fatigue syndrome 25.51 16.35 6 10890 257 90617294
Eosinophilic granulomatosis with polyangiitis 25.24 16.35 10 10886 2520 90615031
Respiratory tract inflammation 24.87 16.35 7 10889 613 90616938
Terminal insomnia 24.17 16.35 8 10888 1207 90616344
Rubber sensitivity 24.13 16.35 10 10886 2827 90614724
Bacterial infection 24.01 16.35 21 10875 23423 90594128
Dyspnoea exertional 23.89 16.35 36 10860 72252 90545299
Blood pressure increased 23.33 16.35 64 10832 197153 90420398
Oropharyngeal pain 23.12 16.35 46 10850 115141 90502410
Cholestasis 23.02 16.35 25 10871 36274 90581277
Premature baby 22.79 16.35 21 10875 25056 90592495
Restrictive pulmonary disease 22.39 16.35 9 10887 2353 90615198
Synovitis 22.37 16.35 6 10890 329746 90287805
Rales 22.14 16.35 17 10879 15810 90601741
Hepatic enzyme increased 21.91 16.35 8 10888 360728 90256823
Allergy to animal 21.76 16.35 8 10888 1646 90615905
Smoke sensitivity 21.61 16.35 6 10890 500 90617051
Haematoma 21.53 16.35 25 10871 39023 90578528
Phlebectomy 21.35 16.35 4 10892 55 90617496
Loss of personal independence in daily activities 21.15 16.35 49 10847 136056 90481495
Abdominal discomfort 21.03 16.35 16 10880 477312 90140239
Antisocial behaviour 20.68 16.35 6 10890 586 90616965
Asthmatic crisis 20.64 16.35 8 10888 1902 90615649
Exposure during pregnancy 20.35 16.35 69 10827 238341 90379210
Spirometry abnormal 20.13 16.35 5 10891 270 90617281
Neonatal respiratory distress syndrome 20.03 16.35 9 10887 3092 90614459
Respiratory rate increased 19.83 16.35 16 10880 15985 90601566
Polyp 19.76 16.35 12 10884 7632 90609919
Drug intolerance 19.72 16.35 15 10881 447576 90169975
Nail discomfort 19.57 16.35 4 10892 88 90617463
Tooth abscess 19.47 16.35 16 10880 16397 90601154
Drug interaction 19.35 16.35 75 10821 276378 90341173
Premature separation of placenta 18.99 16.35 8 10888 2354 90615197
Exposure to SARS-CoV-2 18.71 16.35 8 10888 2444 90615107
Seasonal allergy 18.51 16.35 18 10878 22965 90594586
Respiratory distress 18.31 16.35 23 10873 38923 90578628
Forced expiratory volume abnormal 18.29 16.35 4 10892 123 90617428
Neutropenic sepsis 18.08 16.35 16 10880 18114 90599437
Treatment failure 18.01 16.35 7 10889 303921 90313630
Heart block congenital 17.72 16.35 3 10893 22 90617529
Fear of surgery 17.49 16.35 3 10893 24 90617527
Somnolence 17.39 16.35 60 10836 209024 90408527
Hyperkinesia 17.12 16.35 7 10889 1912 90615639
Infusion related reaction 17.07 16.35 15 10881 416765 90200786
Eosinophilia 16.97 16.35 19 10877 28514 90589037
Pharyngeal swelling 16.88 16.35 12 10884 9932 90607619
Renal tubular necrosis 16.87 16.35 14 10882 14541 90603010
Skin plaque 16.84 16.35 12 10884 9963 90607588
Exposure to allergen 16.70 16.35 5 10891 545 90617006
Orthostatic hypertension 16.39 16.35 5 10891 580 90616971
Impaired healing 16.38 16.35 4 10892 234195 90383356

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 152.81 18.41 101 6061 62213 42552960
Wheezing 111.04 18.41 79 6083 54702 42560471
Chest discomfort 79.54 18.41 69 6093 63547 42551626
Dyspnoea 75.52 18.41 184 5978 442437 42172736
Blood immunoglobulin E increased 72.20 18.41 25 6137 3600 42611573
Cholestasis 65.59 18.41 47 6115 32832 42582341
Hyperkaliuria 48.57 18.41 9 6153 95 42615078
Forced expiratory volume decreased 44.98 18.41 22 6140 7608 42607565
Obstructive airways disorder 43.95 18.41 33 6129 24726 42590447
Exposure during pregnancy 42.62 18.41 22 6140 8526 42606647
Respiratory distress 41.72 18.41 40 6122 41780 42573393
Wolff-Parkinson-White syndrome 40.42 18.41 9 6153 249 42614924
Agranulocytosis 39.82 18.41 34 6128 30578 42584595
Nasal disorder 36.72 18.41 13 6149 1996 42613177
Rhinitis 35.69 18.41 22 6140 11955 42603218
Bronchospasm 34.21 18.41 22 6140 12863 42602310
Cough 33.31 18.41 77 6085 178026 42437147
Asthma-chronic obstructive pulmonary disease overlap syndrome 32.00 18.41 11 6151 1548 42613625
Gastrointestinal mucosal necrosis 31.56 18.41 7 6155 190 42614983
Interstitial lung disease 31.26 18.41 47 6115 78415 42536758
Enterobacter pneumonia 28.82 18.41 8 6154 553 42614620
Death 27.74 18.41 17 6145 471168 42144005
Sputum increased 27.68 18.41 12 6150 3151 42612022
Toxic epidermal necrolysis 27.45 18.41 26 6136 26724 42588449
Heart rate increased 27.29 18.41 36 6126 53219 42561954
Meralgia paraesthetica 27.05 18.41 6 6156 163 42615010
Placental transfusion syndrome 26.98 18.41 4 6158 8 42615165
Sputum discoloured 26.16 18.41 17 6145 10115 42605058
Bronchospasm paradoxical 25.42 18.41 5 6157 74 42615099
Penile erythema 25.11 18.41 6 6156 228 42614945
Middle insomnia 24.90 18.41 15 6147 7818 42607355
Foetal distress syndrome 22.92 18.41 8 6154 1178 42613995
Unmasking of previously unidentified disease 22.64 18.41 8 6154 1221 42613952
Respiratory tract congestion 22.61 18.41 14 6148 7664 42607509
Lung disorder 22.42 18.41 31 6131 47892 42567281
Cyanosis 22.25 18.41 18 6144 15013 42600160
Respiratory rate decreased 22.00 18.41 10 6152 2935 42612238
Nasal inflammation 21.31 18.41 6 6156 437 42614736
Stillbirth 20.75 18.41 5 6157 197 42614976
Subcapsular splenic haematoma 20.16 18.41 4 6158 62 42615111
Ocular myasthenia 19.74 18.41 6 6156 571 42614602
Ductus arteriosus premature closure 19.67 18.41 5 6157 246 42614927
Prothrombin time ratio decreased 19.62 18.41 6 6156 583 42614590
Hepatic vein occlusion 19.42 18.41 5 6157 259 42614914
Premature baby 19.12 18.41 20 6142 23133 42592040

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 265.70 15.75 247 15689 250044 110323319
Dyspnoea 161.32 15.75 433 15503 1106439 109466924
Wheezing 132.23 15.75 173 15763 255057 110318306
Forced expiratory volume decreased 109.01 15.75 48 15888 13128 110560235
Middle insomnia 103.05 15.75 53 15883 20449 110552914
Cough 102.08 15.75 213 15723 461428 110111935
Obstructive airways disorder 89.94 15.75 65 15871 46084 110527279
Chest discomfort 85.57 15.75 115 15821 173733 110399630
Cholestasis 84.80 15.75 72 15864 64446 110508917
Nasal discharge discolouration 79.31 15.75 26 15910 3175 110570188
Sputum discoloured 72.57 15.75 47 15889 27898 110545465
Heart rate increased 72.07 15.75 96 15840 143738 110429625
Lactic acidosis 67.81 15.75 75 15861 92736 110480627
Bronchospasm 66.82 15.75 46 15890 30193 110543170
Decreased activity 65.85 15.75 32 15904 10942 110562421
Blood immunoglobulin E increased 64.30 15.75 28 15908 7454 110565909
Acute kidney injury 63.17 15.75 218 15718 635212 109938151
Full blood count abnormal 60.58 15.75 56 15880 55996 110517367
Productive cough 59.89 15.75 78 15858 114227 110459136
Eosinophil count abnormal 58.38 15.75 16 15920 1058 110572305
Rhinitis 53.87 15.75 36 15900 22509 110550854
Toxic epidermal necrolysis 52.45 15.75 52 15884 56675 110516688
Tremor 48.93 15.75 97 15839 202135 110371228
Respiratory distress 45.77 15.75 53 15883 68821 110504542
Shock haemorrhagic 45.52 15.75 35 15901 27212 110546151
Nasal congestion 43.78 15.75 62 15874 98220 110475143
Hyperkaliuria 42.91 15.75 9 15927 187 110573176
Drug intolerance 38.99 15.75 6 15930 406506 110166857
Blood pressure increased 38.16 15.75 102 15834 258271 110315092
Sleep disorder due to a general medical condition 37.85 15.75 42 15894 52070 110521293
Bronchospasm paradoxical 36.24 15.75 8 15928 213 110573150
Wolff-Parkinson-White syndrome 36.17 15.75 9 15927 407 110572956
Squamous cell carcinoma of the oral cavity 35.55 15.75 10 15926 728 110572635
Tachycardia 33.99 15.75 90 15846 226555 110346808
Hepatocellular injury 33.69 15.75 39 15897 50603 110522760
Terminal insomnia 33.41 15.75 12 15924 1926 110571437
Palpitations 33.36 15.75 72 15864 159140 110414223
Fallopian tube disorder 30.70 15.75 8 15928 436 110572927
Nasal disorder 30.48 15.75 14 15922 4220 110569143
Gastrointestinal mucosal necrosis 30.27 15.75 7 15929 231 110573132
Folate deficiency 29.85 15.75 14 15922 4424 110568939
Alopecia 29.56 15.75 8 15928 364745 110208618
Small intestinal haemorrhage 29.32 15.75 14 15922 4604 110568759
Agranulocytosis 29.05 15.75 40 15896 61720 110511643
Death 28.85 15.75 35 15901 698834 109874529
Lung diffusion disorder 28.80 15.75 7 15929 287 110573076
Haematoma 27.69 15.75 38 15898 58438 110514925
Sinus tachycardia 27.50 15.75 33 15903 44460 110528903
Off label use 27.05 15.75 118 15818 1500067 109073296
Respiratory rate increased 26.98 15.75 25 15911 25058 110548305
Hyperlactacidaemia 26.73 15.75 16 15920 8270 110565093
Penile erythema 26.46 15.75 6 15930 181 110573182
Sputum increased 26.41 15.75 14 15922 5737 110567626
Systemic lupus erythematosus 26.18 15.75 3 15933 254335 110319028
Pleural rub 25.97 15.75 5 15931 66 110573297
Joint swelling 25.75 15.75 16 15920 442829 110130534
Pneumonia 25.37 15.75 214 15722 876500 109696863
Influenza 25.19 15.75 67 15869 169034 110404329
Restrictive pulmonary disease 24.16 15.75 11 15925 3248 110570115
Post viral fatigue syndrome 23.93 15.75 6 15930 280 110573083
Emphysema 23.82 15.75 21 15915 19735 110553628
Enterobacter pneumonia 23.79 15.75 7 15929 598 110572765
Upper-airway cough syndrome 23.54 15.75 19 15917 15838 110557525
Eosinophilia 23.54 15.75 35 15901 57901 110515462
Allergy to animal 22.64 15.75 9 15927 1907 110571456
Smoke sensitivity 22.62 15.75 7 15929 710 110572653
Bronchitis 22.17 15.75 61 15875 156971 110416392
Increased bronchial secretion 22.15 15.75 11 15925 3937 110569426
Glossodynia 21.92 15.75 3 15933 222001 110351362
Forced expiratory volume abnormal 21.89 15.75 5 15931 156 110573207
Rales 21.61 15.75 22 15914 24717 110548646
Interstitial lung disease 21.56 15.75 56 15880 139278 110434085
Treatment failure 20.79 15.75 7 15929 277227 110296136
Tooth abscess 20.74 15.75 19 15917 18770 110554593
Dyspnoea exertional 19.48 15.75 45 15891 104015 110469348
Meralgia paraesthetica 19.36 15.75 6 15930 611 110572752
Pericarditis 19.33 15.75 4 15932 219110 110354253
Polyp 19.30 15.75 14 15922 9966 110563397
Chronic obstructive pulmonary disease 19.12 15.75 46 15890 109112 110464251
Exposure to SARS-CoV-2 18.99 15.75 9 15927 2910 110570453
Nail discomfort 18.72 15.75 4 15932 91 110573272
Stevens-Johnson syndrome 18.57 15.75 28 15908 46873 110526490
Eosinophilic granulomatosis with polyangiitis 18.45 15.75 14 15922 10672 110562691
Hepatic vein occlusion 18.40 15.75 5 15931 320 110573043
Cyanosis 18.28 15.75 22 15914 29719 110543644
Ocular myasthenia 17.99 15.75 6 15930 772 110572591
Oropharyngeal pain 17.57 15.75 51 15885 135225 110438138
Rebound acid hypersecretion 17.54 15.75 4 15932 124 110573239
Respiratory rate decreased 17.42 15.75 11 15925 6247 110567116
Contraindicated product administered 17.38 15.75 7 15929 248260 110325103
Antisocial behaviour 17.35 15.75 6 15930 862 110572501
Product administration error 17.34 15.75 24 15912 37193 110536170
Asthma-chronic obstructive pulmonary disease overlap syndrome 17.28 15.75 11 15925 6333 110567030
Rash maculo-papular 17.21 15.75 35 15901 74187 110499176
Blood cholesterol increased 17.10 15.75 3 15933 184782 110388581
Fear of surgery 16.95 15.75 3 15933 24 110573339
Product dose omission issue 16.87 15.75 13 15923 321769 110251594
Hepatic enzyme increased 16.78 15.75 13 15923 320879 110252484
Systolic hypertension 16.73 15.75 6 15930 958 110572405
Nasal inflammation 16.44 15.75 6 15930 1007 110572356
Tachypnoea 16.29 15.75 24 15912 39371 110533992
Respiratory tract inflammation 16.27 15.75 6 15930 1037 110572326
Unmasking of previously unidentified disease 16.12 15.75 8 15928 2860 110570503
Embolism arterial 16.11 15.75 7 15929 1852 110571511
Abdominal discomfort 15.94 15.75 20 15916 393838 110179525
Rheumatoid arthritis 15.84 15.75 12 15924 299601 110273762
Abdominal wall haematoma 15.81 15.75 10 15926 5695 110567668

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AC03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03CC03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
ATC R03CC53 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D001993 Bronchodilator Agents
MeSH PA D012102 Reproductive Control Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D015149 Tocolytic Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D058666 Adrenergic beta-2 Receptor Agonists
CHEBI has role CHEBI:35522 ฮฒ-adrenergic agonist
CHEBI has role CHEBI:35523 bronchodilator agent
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:38462 EC 3.1.1.7 (acetylcholinesterase) inhibitor
CHEBI has role CHEBI:49167 anti-asthmatic drug
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66993 tocolytic agent
CHEBI has role CHEBI:53784 antispasmodic drug

Related Drugs by ATC class:

R03AC Selective beta-2-adrenoreceptor agonists 17 drugs
bitolterolcarbuterolclenbuterolfenoterolformoterolhexoprenalineindacaterolisoetarineolodaterolpirbuterolprocaterolreproterol show all 17 →
R03CC Selective beta-2-adrenoreceptor agonists 14 drugs
ambroxolbambuterolcarbuterolclenbuterolfenoterolformoterolhexoprenalineisoetarinepirbuterolprocaterolreproterolsalbutamol show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bronchitis indication 32398004 DOID:6132
Tear film insufficiency indication 46152009
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Skin irritation indication 367466007
Asthma management indication 406162001
Itching of skin indication 418363000
Acute exacerbation of asthma indication 708038006
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Minor Skin Wound Pain indication
Bronchospasm Prevention indication
Premature labor off-label use 6383007
Bronchiectasis off-label use 12295008 DOID:9563
Keratoconjunctivitis sicca off-label use 302896008 DOID:12895
Pulmonary edema contraindication 19242006 DOID:11396
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Ketoacidosis contraindication 56051008
Diabetes mellitus contraindication 73211009 DOID:9351
Compression of umbilical cord contraindication 79222000
Hyperglycemia contraindication 80394007 DOID:4195
Decreased respiratory function contraindication 80954004
Epilepsy contraindication 84757009 DOID:1826
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Placental abruption contraindication 415105001
Denuded skin contraindication 418242004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.48 acidic
pKa2 11.49 acidic
pKa3 12.74 acidic
pKa4 8.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST Ki 5.60 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR AGONIST EC50 5.80 IUPHAR
Beta-2 adrenergic receptor GPCR Kd 5.40 CHEMBL

External reference:

IDSource
4019941 VUID
N0000148026 NUI
D00688 KEGG_DRUG
23031-32-5 SECONDARY_CAS_RN
4018396 VANDF
4019941 VANDF
C0039542 UMLSCUI
CHEBI:9449 CHEBI
CHEMBL1760 ChEMBL_ID
DB00871 DRUGBANK_ID
CHEMBL1315867 ChEMBL_ID
D013726 MESH_DESCRIPTOR_UI
5403 PUBCHEM_CID
560 IUPHAR_LIGAND_ID
2616 INN_ID
N8ONU3L3PG UNII
10368 RXNORM
41721 MMSL
5548 MMSL
d00752 MMSL
001812 NDDF
004731 NDDF
24583009 SNOMEDCT_US
372745006 SNOMEDCT_US
45311002 SNOMEDCT_US
N8ONU3L3PG INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-2611 TABLET 2.50 mg ORAL ANDA 23 sections
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-2622 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9375 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9746 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9962 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1311 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1318 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10135-579 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10135-580 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10271-101 INJECTION 1 mg SUBCUTANEOUS ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-121 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-122 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-132 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-133 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0312 TABLET 2.50 mg ORAL ANDA 22 sections
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 59923-615 INJECTION 1 mg SUBCUTANEOUS ANDA 20 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62135-524 TABLET 2.50 mg ORAL ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62135-525 TABLET 5 mg ORAL ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62559-721 TABLET 2.50 mg ORAL NDA authorized generic 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62559-722 TABLET 5 mg ORAL NDA authorized generic 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 63323-665 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 67296-1053 TABLET 2.50 mg ORAL ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71205-938 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71205-939 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71872-7080 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71872-7130 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 24 sections